Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
The American Brain Tumor Association (ABTA) today announced a new partnership with Brain Tumour Foundation of Canada (BTFC) to accelerate brain tumor research. Through this partnership, BTFC will invest in the ABTA research program to co-fund a research project in Canada, focused on improving resection for low-grade glioma.
Always free for patients & caregivers
Gina & Tim Abbas
Caregiver & Anaplastic Astrocytoma Survivor
Donate now and your gift will be matched thanks to the Will Hicks Charitable Association.
